Global Visceral Pain Treatment Market to Reach Up To US$ 16,709.8 Million by 2027, Says Coherent Market Insights (CMI)

SEATTLE–(BUSINESS WIRE)–#VisceralPainTreatment–According to Coherent Market Insights, the global visceral pain treatment market is estimated to be valued at US$ 11,673.8 million in 2020 and is projected to exhibit a CAGR of 5.2% during the forecast period (2020-2027).

Key Trends and Analysis:

The global visceral pain treatment market is expected to witness significant growth, owing to ongoing research & development by pharmaceutical companies for the development of novel treatment and drugs for visceral pain. For instance, in January 2019, Ironwood Pharmaceuticals Inc. announced that ‘LINZESS’ of strength 72 mcg, 145 mcg, and 290 mcg received approval in China for the treatment of IBS-C (IBS with constipation) in adults. AstraZeneca and Ironwood jointly developed and commercialized LINZESS in China.

Key industry players are involved in collaborative licensing agreements to discover & develop a novel drug, which is contributing towards the growth of the market. For instance, in February 2020, DNDi and Novartis AG entered into a collaborative licensing agreement to develop ‘LXE408,’ a potential novel treatment for visceral leishmaniasis. Such collaborations are helping the global visceral pain treatment market grow exponentially.

The rising occurrence of irritable bowel syndrome (IBS) is expected to drive the overall market growth. According to the IFFBD (International Foundation for Gastrointestinal Disorders), up to 10% to 15% of adults across the globe are affected by irritable bowel syndrome each year. However, the inflating costs of drugs and lack of suitable treatment for visceral pain are expected to hamper the market growth.

Request for Sample PDF copy @ https://www.coherentmarketinsights. (Read more…)com/insight/request-sample/4095

Key Market Takeaways:

The global visceral pain treatment market is expected to exhibit a CAGR of 5.26% during the forecast period (2020-2027), owing to the increasing focus of pharmaceutical companies on clinical trials to develop novel drugs for visceral pain. For instance, in March 2018, Arena Pharmaceuticals presented preclinical and phase I data on APD371 for developing pain treatment related to Crohn’s disease at the APS Annual Scientific Summit at San Diego.

North America market for visceral pain treatment is expected to be the most lucrative region during the forecast period, owing to the increasing incidence of Crohn’s disease in the region. For instance, every year, around 400 to 600 cases per 100,000 persons are registered for Crohn’s disease. According to the CDC, around 3 million people in the U.S. were diagnosed with irritable bowel diseases such as Crohn’s disease or ulcerative colitis in 2015.

Competitive Landscape:

Key players operating in the global visceral pain treatment market include Chromocell Corporation, Addex Therapeutics Ltd., Takeda, AstraZeneca, GIcare Pharma Inc., Astellas Pharma Inc., Medestea Research & Production S.p.A., Grunenthal GmbH, Allergan, Abbvie, Neurim Pharmaceuticals Ltd, and Johnson & Johnson.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4095

Market Segmentation:

• Global Visceral Pain Treatment Market, By Drug Type:
  • Pain modifiers
    • Tricyclic Anticonvulsant
    • Tricyclic Antidepressants
  • Analgesics
    • Narcotics
    • NSAID
  • Others
• Global Visceral Pain Treatment Market, By Indication:
  • Irritable bowel syndrome
  • Chronic prostatitis
  • Interstitial cystitis
  • Crohn’s Disease
• Global Visceral Pain Treatment Market, By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Channels
• Global Visceral Pain Treatment Market, By Region:
  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa

Related Market Intelligence Report:

Osteogenesis Imperfecta Treatment Market, by Drugs (Teriparatide, Denosumab, and Others) By Route of Administration (Subcutaneous, Intravenous, Oral, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Read more: https://www.coherentmarketinsights.com/market-insight/osteogenesis-imperfecta-treatment-market-4064

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.

Contacts

Mr. Shah

Senior Client Partner – Business Development

Coherent Market Insights

Phone:

US: +1-206-701-6702

UK: +44-020-8133-4027

Japan: +81-050-5539-1737

India: +91-848-285-0837

Email: [email protected]
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter